Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 4/20 | 0.57 |
| ▸ | WNT3A | P56704 | 4/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29503181 | 1.00 | CTNNB1 (0.57) | CTNNB1WNT3ALCKNAMPTCYP2A6 | |
| SCHEMBL3354553 | 0.85 | LCK (0.48) | CTNNB1WNT3ALCKDYRK1ACHRNA7 | |
| SCHEMBL29503162 | 0.85 | LCK (0.48) | CTNNB1WNT3ALCKDYRK1ACHRNA7 | |
| SCHEMBL30489890 | 0.82 | CTNNB1 (0.63) | CTNNB1WNT3ANAMPTCYP2A6CSNK2A1 | |
| SCHEMBL573187 | 0.82 | CTNNB1 (0.63) | CTNNB1WNT3ANAMPTCYP2A6CSNK2A1 | |
| SCHEMBL30446776 | 0.81 | CTNNB1 (0.57) | CTNNB1WNT3ANAMPTCYP2A6CA2 | |
| SCHEMBL1021640 | 0.81 | CTNNB1 (0.57) | CTNNB1WNT3ANAMPTCYP2A6CSNK2A1 | |
| SCHEMBL826934 | 0.81 | CTNNB1 (0.57) | CTNNB1WNT3ANAMPTCYP2A6CA2 | |
| Hydrochloric Acid SCHEMBL9431978 | 0.79 | F2 (0.48) | CTNNB1WNT3ACYP2A6DYRK1A | |
| SCHEMBL16595380 | 0.79 | CTNNB1 (0.59) | CTNNB1WNT3ANAMPTCYP2A6CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117836306-A | Galactose glycoside derivatives as galectin-3 inhibitors | 株式会社蒂奥姆生物 | 2024-04-05 | — | — | CN | claimed |
| EP-1888595-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-02-20 | — | — | EP | claimed |
| WO-2006110917-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-19 | — | — | WO | claimed |
| CN-117836306-A | Galactose glycoside derivatives as galectin-3 inhibitors | 株式会社蒂奥姆生物 | 2024-04-05 | — | — | CN | disclosed |
| WO-2023277630-A1 | GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR | 주식회사 티움바이오 | 2023-01-05 | — | — | WO | disclosed |
| US-20200071316-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | Kineta Immuno-Oncology LLC | 2020-03-05 | — | — | US | disclosed |
| EP-3394052-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | Kancera AB (SE) | 2018-10-31 | — | — | EP | disclosed |
| EP-2209473-B1 | METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES | GENZYME CORP (US) | 2017-11-22 | — | — | EP | disclosed |
| WO-2017108282-A1 | BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY | KANCERA AB (SE) | 2017-06-29 | — | — | WO | disclosed |
| EP-2167485-B1 | 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2015-09-30 | — | — | EP | disclosed |
| EP-2888249-A1 | SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2015-07-01 | — | — | EP | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060052509-A1 | Composition containing carbon nanotubes having coating thereof and process for producing them | MITSUBISHI RAYON CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| EP-1268484-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
| WO-2001068652-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | CTNNB1 4704/4885WNT3A 4565/4885LCK 588/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | CTNNB1 4704/4885WNT3A 4565/4885LCK 588/4885 |
| US-20200071316-A1 | ACTIVATORS OF THE RETINOIC ACID INDUCIBLE GENE \"RIG-I\" PATHWAY AND METHODS OF USE THEREOF | RARB, RARG, RARA | CTNNB1 4709/4885WNT3A 2898/4885LCK 4191/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | CTNNB1 724/4885WNT3A 1608/4885LCK 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.